IRD

Opus Genetics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$4.06

Price (1 Year)

$6.04 $1.93

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %34.4 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %37.8 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.

Website

Analysis (Turkish): IRD Hissesi Caiz mi, Helal mi? Opus Genetics, Inc. Katılım Analizi